Though the patients recovered from Covid, the 'bad' bacteria that entered to lungs through the throat caused side effects.
"These results demonstrate that S-217622 rapidly eliminates SARS-CoV-2 in patients versus placebo, marking its potential, if approved, as an effective treatment option for Covid-19," said Isao Teshirogi, President and CEO at Shionogi, in a statement.
Copyright © 2024 - Odisha Television Limited All Rights Reserved.
LIVE TV
